BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis

Vernaci, Grazia Maria; Dieci, Maria Vittoria; Manfrin, S.; Mantiero, Mara; Falci, Cristina; Faggioni, Giovanni; Mioranza, Eleonora; Menichetti, Alice; Tasca, Giulia; Griguolo, Gaia; Liso, Elisabetta Di; Saibene, Tania; Michieletto, Silvia; Ghiotto, Cristina; Conte, Pierfranco; Guarneri, Valentina

doi:10.1016/j.breast.2019.07.003

Cited by 20 publications

(24 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 15 patients (13.3%) who received more than one line of ICIs, two patients received anti-PD1 followed by ipilimumab, while the others received ipilimumab followed by anti-PD1. The effect of BMI on OS was not statistically significant (HR=1.00, 95% CI: 0.96 to 1.05, p=0.896) (online supplemental table 4), similar results were obtained considering BMI as a categorical variable (online supplemental table 5). No statistically significant interaction between BMI and gender was found (p value of interaction=0.832).…”

Section: Open Accesssupporting

confidence: 65%

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Rutkowski

Indini

Luca

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundObesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma is controversial. We aim to investigate the prognostic role of body mass index (BMI) in patients with metastatic melanoma receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint inhibitors (ICIs) alone or their sequence.MethodsData on patients with metastatic melanoma receiving ≥1 line of systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall survival (OS) were analyzed by means of multivariable stratified Cox regression models; disease control rate (DCR) was analyzed by multivariable stratified logistic regression models. Subgroup analyzes according to the type of treatments received, and in BRAF-mutated patients were pre-planned. All multivariable models included BMI, age, gender, American Joint Committee on Cancer stage, performance status, lactate dehydrogenase and treatment sequencing strategy as covariates.ResultsBetween November 2010 and November 2018, 688 patients from three Italian and two Polish centers were enrolled. 379 (57%) patients had M1c/d disease, 273 (41%) were female and the mean BMI was 27.1 (SD=4.9). Considering first-line treatment, 446 patients (66.8%) received ICIs and 222 MAPKi. No impact of BMI on OS was detected either considering the first line of ICIs, or ICIs sequencing (HR=1.02, 95% CI: 0.99 to 1.05, p=0.202, and HR=1.02, 95% CI: 0.99 to 1.04, p=0.237, respectively). A late effect of BMI on OS was found in patients treated with MAPKi: for five units increment, a 51% of risk reduction at 18 months and a 76% of risk reduction at 30 months were observed. No significant effect of BMI on PFS and DCR was found in any of the subgroup analyzes.ConclusionIn patients with metastatic melanoma receiving ICIs, there is no impact of BMI on DCR, PFS and OS. The late prognostic effect of BMI in patients treated with MAPKi should be considered hypothesis generating and needs to be further investigated.

show abstract

Section: Open Accesssupporting

confidence: 65%

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Rutkowski

Indini

Luca

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…The strength of this research derives from the methodology used to provide a real and effective lifestyle intervention in BC patients, able to statistically reduce body weight, particularly in overweight and obese women throughout the study period. A better prognosis in obese than in overweight women was seen, in contrast to the vast majority of studies where obesity represented the worst category of patients in terms of death and recurrence [46].…”

Section: Discussionmentioning

confidence: 61%

“…At the first visit, women were weighed and height was measured; arm, waist, and hip circumferences, along with the tricipital, bicipital, subscapular, and suprailiac folds were also measured; BMI, defined as weight in kilograms divided by height in meters squared (kg/m 2 ). Based on the BMI, women were grouped into the weight categories recommended by the World Health Organization (WHO) [46]: underweight (BMI < 18.5 kg/m 2 ), normal-weight (BMI = 18.5-24.9 kg/m 2 ), overweight (BMI = 25-29.9 kg/m 2 ) and obese (BMI ≥ 30 kg/m 2 ). Nutritional history and physical activity (hours/week) were inquired.…”

Section: Study Proceduresmentioning

confidence: 99%

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study

Cortesi

Sebastiani

Iannone

et al. 2020

Cancers

View full text Add to dashboard Cite

Background obesity and sedentary lifestyle have been shown to negatively affect survival in breast cancer (BC). The purpose of this study was to test the efficacy of a lifestyle intervention on body mass index (BMI) and physical activity (PA) levels among BC survivors in Modena, Italy, in order to show an outcome improvement in obese and overweight patients. Methods: This study is a single-arm experimental design, conducted between November 2009 and May 2016 on 430 women affected by BC. Weight, BMI, and PA were assessed at baseline, at 12 months, and at the end of the study. Survival curves were estimated among normal, overweight, and obese patients. Results: Mean BMI decreased from baseline to the end of the study was equal to 2.9% (p = 0.065) in overweight patients and 3.3% in obese patients (p = 0.048). Mean PA increase from baseline to the end of the study was equal to 125% (p < 0.001) in normal patients, 200% (p < 0.001) in overweight patients and 100% (p < 0.001) in obese patients. After 70 months of follow-up, the 5-year overall survival (OS) rate was 96%, 96%, and 93%, respectively in normal, obese, and overweight patients. Overweight patients had significantly worse OS than normal ones (HR = 3.69, 95%CI = 1.82–4.53 p = 0.027) whereas no statistically significant differences were seen between obese and normal patients (HR 2.45, 95%CI = 0.68–8.78, p = 0.169). Conclusions: A lifestyle intervention can lead to clinically meaningful weight loss and increase PA in patients with BC. These results could contribute to improving the OS in obese patients compared to overweight ones.

show abstract

“…As an independent prognostic indicator of tumor-related diseases, BMI has got more and more concern by researchers in recent years. BMI was related with the prognosis of breast carcinoma, non-small-cell lung cancer, and so on [20,21]. In this paper, we found that BMI was signi cantly correlated with the prognosis of AEG patients.…”

Section: Discussionmentioning

confidence: 50%

A simple model established by blood markers predicting overall survival after radical resection of type II and III Adenocarcinomas of the Esophagogastric Junction

Zhang

Wei

2020

Preprint

View full text Add to dashboard Cite

Background. The prognostic prediction after radical resection of Adenocarcinomas of the esophagogastric junction (AEG) has not been well established. We aimed to establish a prognostic model for AEG(type II and III) based on routine markers. Methods. 355 patients who underwent curative AEG at the first affiliated Hospital of Anhui Medical University from January 2010 to January 2011 were included in this study. Univariate and multivariate analysis were used to screen for risk factors. The construction of the nomogram was based on Cox proportional hazard regression models. The new score models was analyzed by C index and Calibration curves. Results. Multivariate analysis showed that TNM stage, NLR and BMI were independent prognostic factors. The new score system had a higher C-index, and the Calibration curves of the nomogram were reliable. Conclusions. Based on the serum markers and other clinical indicators, we developed a precise model to predict the prognosis of patients with AEG(type II and III). This score system can provide effective help for surgeons and patients.

show abstract

BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis

Cited by 20 publications

References 42 publications

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study

A simple model established by blood markers predicting overall survival after radical resection of type II and III Adenocarcinomas of the Esophagogastric Junction

Contact Info

Product

Resources

About